Oncodesign Precision Medicine Société anonyme (EPA: ALOPM)

EPA: ALOPM Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	-	0.32	13.37
Short-Term Investments	-	10.01	-
Cash & Short-Term Investments	-	10.34	13.37
Cash Growth	-	-22.72%	-
Accounts Receivable	-	1.06	0.48
Other Receivables	-	2.68	2.41
Receivables	-	3.74	2.89
Prepaid Expenses	-	0.32	0.14
Other Current Assets	-	-0	-
Total Current Assets	-	14.4	16.41
Property, Plant & Equipment	-	0.76	0.9
Other Intangible Assets	-	1.15	0.79
Other Long-Term Assets	-	0.32	0.27
Total Assets	-	16.63	18.37
Accounts Payable	-	2.89	2.98
Current Income Taxes Payable	-	1.19	0.98
Total Current Liabilities	-	4.08	3.96
Long-Term Debt	-	8.83	2.6
Long-Term Unearned Revenue	-	0.03	-
Other Long-Term Liabilities	-	0	0.02
Total Liabilities	-	12.94	6.59
Common Stock	-	5.7	5.68
Additional Paid-In Capital	-	4.37	4.39
Retained Earnings	-	-8.32	-0.23
Comprehensive Income & Other	-	1.94	1.94
Shareholders' Equity	-	3.69	11.78
Total Liabilities & Equity	-	16.63	18.37
Total Debt	-	8.83	2.6
Net Cash (Debt)	-	1.51	10.77
Net Cash Growth	-	-85.98%	-
Net Cash Per Share	-	0.09	-
Filing Date Shares Outstanding	-	16.66	-
Total Common Shares Outstanding	-	16.63	-
Working Capital	-	10.32	12.45
Book Value Per Share	-	0.22	-
Tangible Book Value	-	2.54	10.99
Tangible Book Value Per Share	-	0.15	-
Land	-	0.11	0.11
Buildings	-	0.25	0.24
Machinery	-	0.86	0.86

Source: S&P Capital IQ. Standard template. Financial Sources.